D-1353-2020 Class II Ongoing
FDA drug recall D-1353-2020 was initiated by Amneal Pharmaceuticals Of New York, LLC on May 29, 2020 and is designated Class II. Reason for recall: CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level The recall status is ongoing.
Recall details
- Product Type
- Drugs
- Report Date
- Jul 1, 2020
- Initiation Date
- May 29, 2020
- Voluntary/Mandated
- Voluntary: Firm initiated
Product description
amneal Metformin Hydrochloride Extended-Release Tablets, USP, 500 mg, 1000 tablets bottles, Manufactured by: Amneal Pharmaceuticals Pvt. Ltd. Ahmedabad, 388213, INDIA Distributed by: Amneal Pharmaceuticals LLC Bridgewater, NJ 08807 NDC 65162-0178-11
Reason for recall
CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level
Distribution pattern
Nationwide
Code information
HF08618A 6/30/2020 HF08718A 6/30/2020 HF15418A 7/31/2020 HF15518A 7/31/2020 HH11818A 9/30/2020 HJ00818A 9/30/2020 HJ00918A 9/30/2020 HJ01018A 9/30/2020
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1353-2020
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026